BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 2011;28:927-59. [PMID: 22057727 DOI: 10.1007/s12325-011-0072-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Harit VK, Ramesh NG. Amino-functionalized iminocyclitols: synthetic glycomimetics of medicinal interest. RSC Adv 2016;6:109528-607. [DOI: 10.1039/c6ra23513a] [Cited by in Crossref: 23] [Article Influence: 3.8] [Reference Citation Analysis]
2 Gao R, Du N, Liu D, Li Z, Zhu Y, Shu Y. Oseltamivir inhibits both viral entry and release but enhances apoptosis of cells infected with influenza A H1N1. Biochemical and Biophysical Research Communications 2013;431:788-95. [DOI: 10.1016/j.bbrc.2013.01.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Ağagündüz D, Çelik MN, Çıtar Dazıroğlu ME, Capasso R. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. Nutrients 2021;13:1550. [PMID: 34064534 DOI: 10.3390/nu13051550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kaddoura M, AlIbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, Haddad S, Eid A, Zaraket H. COVID-19 Therapeutic Options Under Investigation. Front Pharmacol 2020;11:1196. [PMID: 32848795 DOI: 10.3389/fphar.2020.01196] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
5 Li J, Yang Z, Mao LF, Chen RH, Yu XF, Yang XH, Zhang GZ, Wang HQ, Chen SC, Zhao G. Reverse transcription recombinase-aided amplification assay for rapid detection of the influenza A(H1N1)pdm09 H275Y mutation that confers oseltamivir resistance. Mol Cell Probes 2021;60:101771. [PMID: 34560257 DOI: 10.1016/j.mcp.2021.101771] [Reference Citation Analysis]
6 Hofman S, Bolhuis MS, Koster RA, Akkerman OW, van Assen S, Stove C, Alffenaar JC. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis 2015;7:481-95. [DOI: 10.4155/bio.14.318] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
7 Kang HR, Jang SC, Shin JY. Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study. Expert Opin Drug Saf 2021;20:245-53. [PMID: 33183123 DOI: 10.1080/14740338.2021.1850690] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ahout I, Ferwerda G, de Groot R. Elucidation and clinical role of emerging viral respiratory tract infections in children. Adv Exp Med Biol 2013;764:191-204. [PMID: 23654068 DOI: 10.1007/978-1-4614-4726-9_16] [Reference Citation Analysis]
9 Patel K, Rayner CR, Giraudon M, Kamal MA, Morcos PN, Robson R, Kirkpatrick CM. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. Br J Clin Pharmacol 2015;79:624-35. [PMID: 25289522 DOI: 10.1111/bcp.12526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 Rasmussen HB, Bjerre D, Linnet K, Jürgens G, Dalhoff K, Stefansson H, Hankemeier T, Kaddurah-Daouk R, Taboureau O, Brunak S, Houmann T, Jeppesen P, Pagsberg AK, Plessen K, Dyrborg J, Hansen PR, Hansen PE, Hughes T, Werge T; INDICES Consortium. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics 2015;16:649-65. [PMID: 25896426 DOI: 10.2217/pgs.15.7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Masuet-Aumatell C, Toovey S, Zuckerman JN. Prevention of influenza among travellers attending at a UK travel clinic: beliefs and perceptions. A cross-sectional study. Influenza Other Respir Viruses 2013;7:574-83. [PMID: 22998606 DOI: 10.1111/irv.12010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
12 Smee DF, Julander JG, Tarbet EB, Gross M, Nguyen J. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. Antiviral Res 2012;96:13-20. [PMID: 22809862 DOI: 10.1016/j.antiviral.2012.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
13 Cai W, Chen S, Li Y, Zhang A, Zhou H, Chen H, Jin M. 14-Deoxy-11,12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A(H5N1) influenza viruses. Antiviral Research 2016;133:95-105. [DOI: 10.1016/j.antiviral.2016.07.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Labella AM, Merel SE. Influenza. Medical Clinics of North America 2013;97:621-45. [DOI: 10.1016/j.mcna.2013.03.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
15 Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR. The Posology of Oseltamivir in Infants With Influenza Infection Using a Population Pharmacokinetic Approach. Clin Pharmacol Ther 2014;96:380-9. [DOI: 10.1038/clpt.2014.120] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
16 Planz O. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research 2013;98:457-68. [DOI: 10.1016/j.antiviral.2013.04.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
17 Rath BA, Blumentals WA, Miller MK, Starzyk K, Tetiurka B, Wollenhaupt M. A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months. Pharmacoepidemiol Drug Saf 2015;24:286-96. [PMID: 25331369 DOI: 10.1002/pds.3707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Santos J, Brierley S, Gandhi MJ, Cohen MA, Moschella PC, Declan ABL. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review. Viruses 2020;12:E705. [PMID: 32629804 DOI: 10.3390/v12070705] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
19 Dunn AG, Zhou X, Hudgins J, Arachi D, Mandl KD, Coiera E, Bourgeois FT. Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. Journal of Clinical Epidemiology 2016;80:43-9. [DOI: 10.1016/j.jclinepi.2016.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Wang C, Wang H, Liu X, Xu D, Tang Y, Luo P. Traditional Chinese medicine for the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials. J Tradit Chin Med 2014;34:527-31. [PMID: 25417400 DOI: 10.1016/s0254-6272(15)30057-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
21 Gillman A. Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir. Infect Ecol Epidemiol 2016;6:32870. [PMID: 27733236 DOI: 10.3402/iee.v6.32870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Handel A, Ebell MH. Neuraminidase inhibitors for influenza: fully evaluating benefits and harms. Lancet Respir Med 2015;3:e7-8. [PMID: 25773218 DOI: 10.1016/S2213-2600(15)00066-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 López-Medrano F, Fariñas MC, Payeras A, Pachón J. Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic. Enferm Infecc Microbiol Clin 2012;30 Suppl 4:49-53. [PMID: 23116793 DOI: 10.1016/S0213-005X(12)70105-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Reich S, Guilligay D, Cusack S. An in vitro fluorescence based study of initiation of RNA synthesis by influenza B polymerase. Nucleic Acids Res 2017;45:3353-68. [PMID: 28126917 DOI: 10.1093/nar/gkx043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
25 Loukotková L, Basavarajappa M, Lumen A, Roberts R, Mattison D, Morris SM, Fisher J, Beland FA, Gamboa da Costa G. Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. Regul Toxicol Pharmacol 2020;112:104569. [PMID: 31927005 DOI: 10.1016/j.yrtph.2019.104569] [Reference Citation Analysis]
26 Reddy MB, Yang KH, Rao G, Rayner CR, Nie J, Pamulapati C, Marathe BM, Forrest A, Govorkova EA. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PLoS One 2015;10:e0138069. [PMID: 26460484 DOI: 10.1371/journal.pone.0138069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Decorte BL. Underexplored Opportunities for Natural Products in Drug Discovery: Miniperspective. J Med Chem 2016;59:9295-304. [DOI: 10.1021/acs.jmedchem.6b00473] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
28 Song R, Pang X, Yang P, Shu Y, Zhang Y, Wang Q, Chen Z, Liu J, Cheng J, Jiao Y, Jiang R, Lu L, Chen L, Ma J, Li C, Zeng H, Peng X, Huang L, Zheng Y, Deng Y, Li X. Surveillance of the first case of human avian influenza A (H7N9) virus in Beijing, China. Infection 2014;42:127-33. [PMID: 24129555 DOI: 10.1007/s15010-013-0533-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One 2013;8:e60348. [PMID: 23565231 DOI: 10.1371/journal.pone.0060348] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
30 Imperiale MJ, Hanna MG 3rd. Biosafety considerations of mammalian-transmissible H5N1 influenza. mBio 2012;3:e00043-12. [PMID: 22396482 DOI: 10.1128/mBio.00043-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Van Wesenbeeck L, Meeuws H, Van Immerseel A, Ispas G, Schmidt K, Houspie L, Van Ranst M, Stuyver L. Comparison of the FilmArray RP, Verigene RV+, and Prodesse ProFLU+/FAST+ multiplex platforms for detection of influenza viruses in clinical samples from the 2011-2012 influenza season in Belgium. J Clin Microbiol 2013;51:2977-85. [PMID: 23824777 DOI: 10.1128/JCM.00911-13] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
32 Bueno M, Calvo C, Méndez-Echevarría A, de José MI, Santos M, Carrasco J, Tovizi M, Guillén S, de Blas A, Llorente M, Tarrago A, Escosa L, Cilleruelo MJ, Tomatis C, Blazquez D, Otheo E, Mazagatos D, García-García ML. Oseltamivir treatment for influenza in hospitalized children without underlying diseases. Pediatr Infect Dis J 2013;32:1066-9. [PMID: 23722530 DOI: 10.1097/INF.0b013e31829be4bc] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
33 Liyanage R, Jayawardana BC, Kodithuwakku SP. Potential Novel Therapeutics: Some Biological Aspects of Marine-derived Bioactive Peptides. In: Kim S, editor. Marine Proteins and Peptides. Chichester: John Wiley & Sons, Ltd; 2013. pp. 323-49. [DOI: 10.1002/9781118375082.ch15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Baldo A, Leunda A, Thi CDD, Breyer D, Pauwels K, Welby S, Van Vaerenbergh B, Herman P. Biosafety Risk Assessment and Management of Laboratory-Derived Influenza A (H5N1) Viruses Transmissible in Ferrets. Appl Biosaf 2013;18:6-17. [DOI: 10.1177/153567601301800102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Zhou X, Wang Y, Tsafnat G, Coiera E, Bourgeois FT, Dunn AG. Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol 2015;68:87-93. [PMID: 25450452 DOI: 10.1016/j.jclinepi.2014.09.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Çiftçi E, Karbuz A, Kendirli T. Influenza and the use of oseltamivir in children. Turk Pediatri Ars 2016;51:63-71. [PMID: 27489462 DOI: 10.5152/TurkPediatriArs.2016.2359] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]